Clinical Trials: Country-Specific Clinical Trials

Multi-Regional Clinical Trials Including China: Best Practices

Posted on digi By digi

Sponsors should:
✔️ Engage NMPA early for protocol and patient enrollment guidance
✔️ Select sites based on MRCT readiness and ethics capacity
✔️ Implement bilingual systems for CRFs and TMFs
✔️ Train investigators in ICH E17 MRCT principles
✔️ Partner with CROs for operational support and inspections
✔️ Monitor recruitment diversity to meet global regulatory expectations
These practices ensure successful integration of Chinese data into global MRCTs.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

China’s Role in ICH E17 MRCT Guidelines Implementation

Posted on digi By digi

Sponsors should:
✔️ Engage with the NMPA early for MRCT protocol review
✔️ Allocate sufficient Chinese patient enrollment for subgroup analysis
✔️ Harmonize CRFs and TMFs with global CDISC standards
✔️ Prepare Chinese sites for multinational inspections
✔️ Partner with CROs with strong China expertise
✔️ Incorporate bilingual training for investigators and site staff
These practices ensure successful implementation of ICH E17 in China.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Import & Export Licensing of Investigational Products in China

Posted on digi By digi

Sponsors should:
✔️ Begin licensing applications well in advance of trial initiation
✔️ Engage CROs and logistics vendors with China-specific expertise
✔️ Verify accuracy of all documentation before shipment
✔️ Train site staff on customs clearance and chain-of-custody requirements
✔️ Build contingency timelines for potential delays
These preventive measures ensure timely trial initiation and compliance with regulatory expectations.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Local Manufacturing Requirements for IMPs in Chinese Clinical Trials

Posted on digi By digi

Sponsors should:
– Select NMPA-accredited GMP facilities early in planning.
– Validate manufacturing and packaging processes before trial initiation.
– Ensure all labeling complies with Mandarin-language requirements.
– Audit local manufacturers and CROs regularly for compliance.
– Maintain complete batch records and stability data.
– Train staff in GMP, GSP, and clinical supply chain requirements.
These measures safeguard compliance and ensure uninterrupted IMP supply.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Timelines for IND vs NDA Clinical Development in China

Posted on digi By digi

Sponsors should:
– Plan IND submissions well in advance with complete preclinical data.
– Anticipate NMPA queries and prepare responses before submission.
– Leverage accelerated pathways for breakthrough or rare disease therapies.
– Prepare GMP and GCP inspections early during NDA preparation.
– Align with CROs for dossier preparation and submission in eCTD format.
These best practices ensure smoother navigation of IND and NDA timelines.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Site Selection Strategy in China’s Expanding Research Network

Posted on digi By digi

Sponsors should:
– Balance site selection between Tier-1 and Tier-2 hospitals.
– Conduct robust feasibility and patient pool assessments.
– Verify site accreditation and ethics committee capacity.
– Provide additional training and monitoring for less experienced sites.
– Partner with CROs for site evaluation and operational support.
– Audit site compliance during initiation to ensure readiness.
These best practices reduce risks and enhance trial efficiency.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Patient Informed Consent Challenges in Rural China

Posted on digi By digi

Sponsors should:
– Develop simplified consent forms with plain language and visuals.
– Translate documents into local dialects where needed.
– Implement eConsent tools with video and interactive features.
– Provide investigator training in communication and cultural sensitivity.
– Involve patient advocacy groups to review consent materials.
– Monitor rural sites closely for consent compliance.
These practices strengthen informed consent processes and protect patient rights.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

How Traditional Medicine Trials Are Evaluated by NMPA

Posted on digi By digi

Sponsors should:
– Standardize herbal raw material sourcing and quality testing.
– Design hybrid endpoints combining TCM and biomedical measures.
– Train investigators in both TCM diagnostics and GCP standards.
– Engage ethics committees early to validate culturally relevant trial designs.
– Document historical use alongside clinical trial data.
– Implement rigorous pharmacovigilance systems for multi-herbal formulations.
These strategies improve trial credibility and regulatory acceptance.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Bioequivalence Trials for Generics in China: Case Examples

Posted on digi By digi

Sponsors should:
– Partner with NMPA-accredited sites and GLP-certified laboratories.
– Standardize sample collection and handling procedures.
– Validate all PK assays before trial initiation.
– Conduct mock inspections to test data integrity.
– Train site staff in protocol compliance and EDC systems.
– Ensure diet and fasting conditions are strictly monitored during dosing.
These practices minimize risks of inspection findings and trial delays.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Outsourcing Trends: Global CROs vs Local CROs in China

Posted on digi By digi

Sponsors should:
– Conduct rigorous due diligence on CROs’ regulatory compliance history.
– Balance trial needs with CRO strengths—global for multinational oversight, local for operational execution.
– Implement strong oversight mechanisms and QA audits for CRO partners.
– Use hybrid outsourcing models where appropriate to maximize efficiency.
– Ensure CRO staff are trained in ICH E6(R2) and NMPA-specific requirements.
– Establish clear contractual obligations for data integrity and inspection readiness.
These practices enhance collaboration and reduce outsourcing risks.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials